Business Description
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Business History
Price Overview
Last updated: May 11, 2026 1:58pm (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -4.73
Total Equity: $15.76M
Shares: 3,281,915
Total Debt: $48,774
Cash: $5.22M
EBITDA: -$6.33M
Total Debt: $48,774
Cash: $5.22M
Revenue: $815,371
Revenue: $815,371
Revenue: $815,371
Total Equity: $15.76M
Tax Rate: 0.0%
Equity: $15.76M
Total Debt: $48,774
Cash: $5.22M
Current Liabilities: $9.14M
Long-Term Debt: $24,362
Total Debt: $48,774
Total Equity: $15.76M
Shares: 3,281,915
Shares: 3,281,915
CapEx: $0.00
Shares: 3,281,915
Stock Price: $0.38
Net Income: -$14.03M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $58,465 | $2.5M | $815,371 |
| Cost of Revenue | $4,890 | $6,752 | $1.2M | $1.5M | $182,458 |
| Gross Profit | $-4,890 | $-6,752 | -$1.1M | $1.1M | $632,913 |
| Operating Expenses | $3.4M | $13.5M | $34.9M | $57.5M | $7.0M |
| Operating Income | -$3.4M | -$13.5M | -$36.0M | -$56.5M | -$6.3M |
| Net Income | -$3.4M | -$13.4M | -$37.4M | -$58.7M | -$14.0M |
| EBITDA | -$3.4M | -$13.4M | -$36.7M | -$57.6M | -$6.3M |
| EPS | $-0.09 | $-0.31 | $-25.03 | $-520.93 | $-4.73 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.9M | $25.8M | $4.6M | $646,500 | $5.2M |
| Total Current Assets | $3.1M | $26.3M | $5.8M | $950,267 | $6.1M |
| Total Assets | $3.1M | $26.3M | $87.5M | $28.2M | $24.9M |
| Current Liabilities | $1.6M | $3.9M | $17.2M | $18.3M | $9.1M |
| Long-Term Debt | $0 | $0 | $118,857 | $0 | $24,362 |
| Total Liabilities | $1.6M | $3.9M | $86.1M | $18.6M | $9.2M |
| Total Equity | $1.4M | $22.4M | -$5.6M | $9.6M | $15.8M |
| Retained Earnings | -$6.0M | -$19.4M | -$56.8M | -$115.7M | -$131.2M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$2.0M | -$8.7M | -$13.6M | -$10.5M | -$9.7M |
| Capital Expenditure | $-1,924 | $-9,339 | $-55,044 | $-28,471 | $0 |
| Free Cash Flow | -$2.0M | -$8.7M | -$13.6M | -$10.5M | -$9.7M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $-566,810 | $-58,981 | $-718 | $0 |
| Net Change in Cash | -$2.4M | $23.8M | -$21.2M | -$3.9M | $4.6M |
Analyst Estimates (Annual)
| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$800,000 $800,000 – $800,000
|
$815,371 $815,371 – $815,371
|
$881,218 $881,218 – $881,218
|
$952,384 $952,384 – $952,384
|
| EBITDA |
$-159,999 $-159,999 – $-159,999
|
$-163,074 $-163,074 – $-163,074
|
$-176,243 $-176,243 – $-176,243
|
$-190,476 $-190,476 – $-190,476
|
| Net Income |
-$47.4B -$47.4B – -$47.4B
|
-$55.2B -$55.2B – -$55.2B
|
-$65.8B -$65.8B – -$65.8B
|
-$70.3B -$70.3B – -$70.3B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | +4,217.3% | -67.7% |
| Gross Profit Growth | -38.1% | -16,593.8% | +193.6% | -40.0% |
| Operating Income Growth | -294.5% | -167.3% | -56.8% | +88.8% |
| Net Income Growth | -292.7% | -178.8% | -56.9% | +76.1% |
| EBITDA Growth | -293.1% | -173.7% | -56.9% | +89.0% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-21 | HRT FINANCIAL LP | S-Sale | 49,710.00 | $0.69 | $34,300 |
| 2026-04-17 | HRT FINANCIAL LP | P-Purchase | 34,636.00 | $0.73 | $25,284 |
| 2026-04-16 | HRT FINANCIAL LP | S-Sale | 53,867.00 | $0.73 | $39,323 |
| 2026-04-20 | HRT FINANCIAL LP | S-Sale | 94,462.00 | $0.75 | $70,847 |
| 2026-04-15 | HRT FINANCIAL LP | P-Purchase | 92,554.00 | $0.76 | $70,341 |
| 2026-04-14 | HRT FINANCIAL LP | P-Purchase | 74,350.00 | $0.77 | $57,250 |
| 2026-04-14 | HRT FINANCIAL LP | 0.00 | $0.00 | $0 | |
| 2026-03-18 | White David Allan | 0.00 | $0.00 | $0 | |
| 2026-03-19 | DORF SAMMY | 0.00 | $0.00 | $0 | |
| 2025-12-05 | Romano Sarah | 0.00 | $0.00 | $0 | |
| 2025-08-15 | Oakley Andrew John | A-Award | 618.00 | $0.00 | $0 |
| 2025-08-15 | Oakley Andrew John | J-Other | 20.00 | $0.00 | $0 |
| 2025-08-15 | Tarsh Simon | A-Award | 618.00 | $0.00 | $0 |
| 2025-08-15 | Tarsh Simon | J-Other | 39.00 | $0.00 | $0 |
| 2025-08-15 | Meier Thomas | A-Award | 618.00 | $0.00 | $0 |
| 2025-08-15 | Meier Thomas | J-Other | 39.00 | $0.00 | $0 |
| 2025-08-15 | Ramdeen Timothy R. | A-Award | 618.00 | $0.00 | $0 |
| 2025-08-15 | Ramdeen Timothy R. | J-Other | 39.00 | $0.00 | $0 |
| 2025-07-14 | Altos Venture AG | J-Other | 241,514.00 | $0.00 | $0 |
| 2025-07-14 | Altos Venture AG | J-Other | 241,514.00 | $0.00 | $0 |